The Company expects to initiate first-in-human study in early 2026, with initial data anticipated H2 2026 Clinical Trial Application (CTA) submission marks the advancement of Tangram’s GalOmic RNAi platform into clinical development Nov. 26, 2025 -- Tangram Therapeutics (‘Tangram’), a company committed to uniting computation and RNAi to make better medicines faster, today announced the submission of a Clinical Trial Application (CTA) to the Medicines and Healthcare products Regulatory Agency (

Nov. 25, 2025 -- Nuvectis Pharma, Inc. (NASDAQ: NVCT, the “Company”), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that the Company will host a virtual Key Opinion Leader Meeting on Tuesday, December 2, 2025 at 8:00 AM ET to discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, including the combination with osimertinib in non-small cell l

Scilex closed the second tranche, purchasing a pre-funded warrant exercisable for 263,914,094 shares of Datavault AI Inc. (Nasdaq: DVLT; “Datavault AI”) common stock in Bitcoin (BTC) (based on the spot exchange rate of BTC as of the signing of the strategic investment). The closing followed the approval by the Datavault AI stockholders, obtained at Datavault AI’s November 24, 2025 annual meeting, of the issuance of the shares of Datavault common stock upon exercise of the pre-funded warrant. Sci

Nov. 26, 2025 -- Mural Oncology plc (Nasdaq: MURA) (“Mural”) announces that, in accordance with the terms of the transaction agreement between XOMA Royalty Corporation (Nasdaq: XOMA) (“XOMA Royalty”), XRA 5 Corp. (“Sub”) and Mural announced on August 20, 2025 (the “Transaction Agreement”), the Additional Price Per Share (as defined in the Transaction Agreement) has been finally determined in accordance with Clause 2.4 of the Transaction Agreement as $0.000. As a result, the total cash considera

Nov. 25, 2025 -- Macomics Ltd, a leader in macrophage drug discovery, announces that it has validated its ENIGMAC™ platform in macrophage mediated antifibrotic therapy. Macomics’ ENIGMAC drug discovery platform is designed to discover therapeutic targets and unlock disease specific target biology. The platform enables identification and validation of novel targets and provides a translationally relevant path to the clinic through the development of more physiologically relevant human models co

Data from the KT-621 BROADEN2 Phase 2b AD patient trial expected to be reported by mid-2027 KT-621 BREADTH Phase 2b trial in asthma on track to initiate in 1Q26 Completed dosing in KT-621 BroADen Phase 1b AD trial with data to be reported in December 2025 Nov. 25, 2025 -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it recently initiated dosi

Publication details large multicenter clinical trial demonstrating significant reductions in IBS symptoms through inFoods IBS guided dietary therapy Nov. 25, 2025 -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical diagnostic solutions, is proud to announce that its inFoods® IBS diagnostic-guided therapy product is being featured in the Fall 2025 issue of Biotherapeutics Quarterly, a Henry Schein publication. The article, titled “Precision Medicine for IBS: A Novel, IBS-Sp

Successful completion of two-species toxicology studies confirms no systemic organ toxicity, advancing the Company towards its planned regulatory submissions to Israel and Germany Company remains on track to initiate Phase 2/3 clinical trial in locally advanced pancreatic cancer in Q2 2026 Nov. 25, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company developing RNA interference (RNAi) therapies for KRAS-driven cancers, toda

Following the positive opinions of the Committee for Medicinal Products for Human Use (CHMP), the European Commission has granted marketing authorizations for Teva’s biosimilars PONLIMSI and DEGEVMA expanding access to important bone health treatments across Europe These approvals mark another significant milestone in Teva’s strong biosimilars portfolio, in line with Teva's Pivot to Growth Strategy The approvals underscore Teva’s commitment to broadening access to biosimilars Nov. 25, 2025 --

Located at the Daresbury site of the renowned UK-based Science and Technology Facilities Council (STFC), with $300+ million invested to date in developing the technology Nov. 25, 2025 -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT) a biotech company focused on advancing cancer treatments, today announced it has completed the acquisition of Liora Technologies Europe Ltd., a UK-based company pioneering electronically controlled proton therapy systems for treating